IPX066: a new intermediate- and extended-release carbidopa–levodopa formulation
نویسندگان
چکیده
منابع مشابه
Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
A pharmacodynamic model is presented to describe the motor effects (tapping rate, Unified Parkinson's Disease Rating Scale [UPDRS] Part III, and investigator-rating of ON/OFF, including dyskinesia) of levodopa (LD) in patients with advanced idiopathic Parkinson's disease (PD) treated with immediate-release (IR) carbidopa-levodopa (CD-LD) or an extended-release (ER) formulation of CD-LD (IPX066)...
متن کاملFormulation and Evaluation of Extended- Release Tablet of Zolpidem Tartrate by Wet Granulation Technique
The goal of this study was to design and evaluate extended - release system of the hypnotic agent, Zolpidemtartrate usefulness for the treatment of insomnia. The half-life of this drug is about 1.9 - 3 hours that indicatingit a candidate for the extended release formulation. Our investigation relates to development of extendeddrug delivery system based on Hydroxy propyl methyl cellulose (HPMCK4...
متن کاملFormulation and In Vitro Evaluation of Extended Release Tablets of Paliperidone Using Natural Gums
Paliperidone is a well known dopamine antagonist of the atypical antipsychotic class. In the present study Paliperidone was formulated as ER release tablets using natural and synthetic polymers separately or in combination. The aim of ER release formulation is to reduce the frequency of dosing. Tablets are prepared by direct compression method. The optimized formulations contain Paliperidone as...
متن کاملA new extended release formulation (OROS®) of hydromorphone in the management of pain
Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects t...
متن کاملPramipexole and its Extended Release Formulation for Parkinson’s Disease
Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantage...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurodegenerative Disease Management
سال: 2013
ISSN: 1758-2024,1758-2032
DOI: 10.2217/nmt.13.4